

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: **Organic Flower Investments Group Inc.** (the “Issuer”).

Trading Symbol: **SOW**

This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

Third quarter (nine month period) ended March 31, 2019.

Unaudited condensed interim consolidated financial statements of the Issuer for the nine month period ended March 31, 2019, as filed with securities regulatory authorities, are attached to this Form 5 - Quarterly Listing Statement as Appendix A.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

With respect to related party transactions for information supplementary to that contained in the notes to the unaudited condensed interim consolidated financial statements, which are attached hereto, please refer to Management's Discussion & Analysis for the nine month period ended March 31, 2019, as filed with securities regulatory authorities and attached to this Form 5 - Quarterly Listing Statement as Appendix B.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

As at January 15, 2019, the date of the Issuer's last Form 2A - Listing Statement, 112,691,280 common shares in the capital of the Issuer were issued and outstanding.

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
March 8, 2019	Common shares	Exercise of warrants	250,000	\$0.075	\$18,750	Cash	Non-arm's length party	N/A
March 11, 2019	Common shares	Exercise of warrants	700,000	\$0.075	\$52,500	Cash	Non-arm's length party	N/A
March 12, 2019	Common shares	Exercise of warrants	250,000	\$0.075	\$18,750	Cash	Non-arm's length party	N/A
March 18, 2019	Units ⁽¹⁾	Acquisition of 1180782 B.C. Ltd. d/b/a Delta Organic Cannabis ("DOC")	54,687,503	\$0.24	N/A	Acquisition of DOC	Non-arm's length parties	5,468,750 common shares issued as noted below.
March 18, 2019	Common shares	Finders fees paid in connection with acquisition of DOC	5,468,750	\$0.24	N/A	N/A	Consultant	Shares issued as payment of finders fee
March 25, 2019	Common shares	Exercise of warrants	1,292,608	\$0.075	\$96,945.60	Cash	Non-arm's length parties	N/A

(1) Each Unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Issuer at an exercise price of \$0.65 until December 5, 2020.

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
March 6, 2019	1,000,000	N/A	Consultant	\$0.45	March 6, 2024	\$0.56

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

As at March 31, 2019, the authorized capital of the Issuer consisted of an unlimited number of common shares without par value, and without any special rights or restrictions, of which 175,540,141 common shares were issued and outstanding.

The holders of common shares are entitled to receive notice of and to attend all meetings of the shareholders of the Issuer and are entitled to one vote in respect of each common share held at such meetings. Subject to the rights, if any at the time, of shareholders holding shares with special rights as to dividends (none of which are authorized or outstanding at the date of this Quarterly Listing Statement), holders of common shares of the Issuer are entitled to dividends as and when declared by the directors. Subject to the rights of holders of any shares ranking in priority to or on a parity with the common shares, the holders of common shares are entitled to participate ratably in any distribution of property or assets upon the liquidation, winding-up or other dissolution of the Issuer.

- (b) number and recorded value for shares issued and outstanding,

Date	Number of common shares	Recorded value of common shares
March 31, 2019	175,340,141	65,808,274

- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

Options:

Options to purchase common shares in the capital of the Issuer are granted by the Issuer's Board of Directors to eligible persons pursuant to the Issuer's Stock Option Incentive Plan.

As at March 31, 2019, the following options were outstanding entitling holders to purchase common shares in the capital of the Issuer as summarized below:

Date of Grant	Number of Options	Exercise Price	Expiry Date	Recorded Value
September 20, 2018	3,564,112	\$0.16	September 20, 2028	\$479,137
July 4, 2016	240,000	\$0.175	July 4, 2021	\$31,326
March 6, 2019	1,000,000	\$0.45	March 6, 2024	\$Nil
TOTAL	4,804,112			

Warrants:

As at March 31, 2019, the following warrants were outstanding entitling holders to purchase common shares in the capital of the Issuer as summarized below:

Date of Issue	Number of Warrants	Exercise Price	Expiry Date	Recorded Value
August 21, 2018	24,628,140	\$0.05	June 16, 2021	\$Nil
August 21, 2018	56,537,816	\$0.075	August 21, 2023	\$Nil
December 5, 2018	18,012,966	\$0.65	December 5, 2020	\$Nil
March 18, 2019	54,687,503	\$0.65	December 5, 2020	\$12,361,493
TOTAL	153,866,425			

Convertible Securities

The Issuer has no convertible securities outstanding.

- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

As at March 31, 2019, no common shares of the Issuer were held in a escrow, a pooling agreement or had any other restriction on transfer.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name of Director/Officer	Position with Issuer
Joel Dumaesq	CEO, interim CFO and Director
Theo van der Linde	Director
John Martin	Director
Brendan Purdy	Director

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

Management's Discussion & Analysis for the nine month period ended March 31, 2019, as filed with securities regulatory authorities, is attached to this Form 5 - Quarterly Listing Statement as Appendix B.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated **May 30, 2019**.

Joel Dumaresq

Name of Director or Senior Officer

"Joel Dumaresq"

Signature

CEO and Director

Official Capacity

Issuer Details Name of Issuer	For Quarter Ended	Date of Report YY/MM/D
Organic Flower Investments Group Inc.	March 31, 2019	2019/05/30
Issuer Address		
789 West Pender Street, Suite 810		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, British Columbia V6C 1H2	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Theo van der Linde	Director	604.336.3196
Contact Email Address theo@pashleth.com	Web Site Address n/a	

APPENDIX A

ORGANIC FLOWER INVESTMENTS GROUP INC.

**Unaudited condensed interim financial statements
for the nine month period ended March 31, 2019**

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)

Unaudited Condensed Interim Consolidated Financial Statements
For the period ended March 31, 2019 and 2018
(Expressed in Canadian Dollars)

REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Organic Flower Investments Group Inc. (formerly Q Investments Ltd.) (the “Company” or “OFIG”) have been prepared by and are the responsibility of the Company’s management.

The Company’s independent auditor has not performed a review of these financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of condensed interim consolidated financial statements by an entity’s auditor.

ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Unaudited - Expressed Canadian Dollars)

	Notes	March 31, 2019	June 30, 2018 (note 12 - restated)	July 1, 2017 (note 12 - restated)
ASSETS				
Current Assets				
Cash		\$ 2,604,502	\$ 1,933	\$ 39,753
Amounts receivable		28,362	-	-
Investments	7	49,584,888	1,296,791	1,697,839
Total assets		\$ 52,217,752	\$ 1,298,724	\$ 1,737,592
LIABILITIES				
Current Liabilities				
Accounts payable and accrued liabilities		\$ 137,325	\$ 45,417	\$ 29,291
		137,325	45,417	29,291
Long Term Liabilities				
Liability portion of convertible debentures	8	-	1,579,095	1,325,705
Total liabilities		137,325	1,624,512	1,354,996
SHAREHOLDERS' EQUITY (DEFICIENCY)				
Share capital	9	65,808,274	27,300,931	27,300,931
Equity portion of convertible debentures	8	-	1,509,607	1,509,607
Contributed surplus	9	13,165,806	102,165	102,165
Deficit		(24,893,653)	(29,238,491)	(28,530,107)
Total shareholders' equity (deficiency)		52,080,427	(325,788)	382,596
Total liabilities and shareholders' equity (deficiency)		\$ 52,217,752	\$ 1,298,724	\$ 1,737,592

Nature of operations and going concern (Note 1)

Subsequent events (Note 13)

Approved on behalf of the Board on May 30, 2019:

"Brendan Purdy"

Director – Brendan Purdy

"Theo Van Der Linde"

Director – Johannes (Theo) Van Der Linde

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE
INCOME (LOSS)
(Unaudited - Expressed in Canadian Dollars)

		For the three months ended		For the nine months ended	
	Notes	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
			(note 12 - restated)		(note 12 - restated)
Net investment gain (loss)					
Fair value gain (loss) change in investments	7	\$ 8,410,045	\$ (730,010)	\$ 7,701,177	\$ 714,787
Gain (loss) on sale of investments	7	(769,180)	22,564	(769,180)	82,996
		7,640,865	(707,446)	6,931,997	797,783
Expenses					
Accretion of convertible debentures	8	-	(13,242)	(159,191)	(40,314)
Consulting		(199,668)	-	(214,918)	-
Management and administrative	10	5,000	(16,841)	(33,929)	(41,841)
Filing and transfer fees		(22,522)	(6,026)	(88,236)	(28,074)
Foreign exchange loss		1,621	884	(1,187)	859
Office and other miscellaneous		(22,643)	(167)	(23,048)	(333)
Professional fees		(200,990)	(5,335)	(320,312)	(28,335)
Share-based compensation	9	-	-	(479,137)	-
Travel		-	-	-	(3,054)
Transaction costs		(2,351,562)	-	(2,351,562)	-
Interest on convertible debt	8	-	(49,238)	(28,996)	(149,902)
		(2,790,764)	(89,965)	(3,700,516)	(290,994)
Net income (loss) for the period		4,850,101	(797,411)	3,231,481	(506,789)
Loss on conversion of convertible loan	8	-	-	(886,643)	-
Net income (loss) and comprehensive income (loss) for the period		\$ 4,850,101	\$ (797,411)	\$ 2,344,838	\$ (506,789)
Income (loss) and comprehensive income (loss) per share, basic		\$ 0.04	\$ (0.13)	\$ 0.03	\$ (0.08)
Income (loss) and comprehensive income (loss) per share, diluted		\$ 0.04	\$ (0.13)	\$ 0.03	\$ (0.08)
Weighted average number of shares outstanding		121,740,543	6,120,190	87,833,503	6,120,190

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)
(Unaudited - Expressed in Canadian Dollars)

	Number of Shares	Share Capital	Equity Portion of Convertible Debentures	Contributed Surplus	Deficit	Shareholders' Equity (Deficiency)
Balance, June 30, 2017 (note 12 – restated)	6,120,190	\$ 27,300,931	\$ 1,509,607	\$ 102,165	\$ (28,530,107)	\$ 382,596
Income and comprehensive income for the period	-	-	-	-	506,789	506,789
Balance, March 31, 2018	6,120,190	\$ 27,300,931	\$ 1,509,607	\$ 102,165	\$ (28,023,318)	\$ 889,385
Balance, June 30, 2018 (note 12 – restated)	6,120,190	\$ 27,300,931	\$ 1,509,607	\$ 102,165	\$ (29,238,491)	\$ (325,788)
Share based compensation	-	-	-	479,137	-	479,137
Private placement, net	77,259,190	8,491,126	-	-	-	8,491,124
Conversion of convertible debt	26,625,000	3,727,500	(1,509,607)	-	-	2,217,893
Shares issued on warrant exercise	4,819,488	311,540	-	-	-	311,540
Shares issued on option exercise	360,000	63,000	-	-	-	63,000
Fair value reclassification pursuant to option exercise	-	46,989	-	(46,989)	-	-
Shares issued for acquisition of DOC	54,687,503	23,515,626	-	12,631,493	-	36,147,119
Transaction costs	5,468,770	2,351,562	-	-	-	2,351,563
Income and comprehensive income for the period	-	-	-	-	2,344,838	2,344,838
Balance, March 31, 2019	175,340,141	\$ 65,808,274	\$ -	\$ 13,165,806	\$ (26,893,653)	\$ 52,080,427

The accompanying notes are an integral part of these condensed consolidated interim financial statements

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

Nine month period ended	March 31, 2019	March 31, 2018 (note 12 – restated)
Operating activities		
Net income and comprehensive income for the period	\$ 2,344,838	\$ 506,789
Items not affecting cash:		
Share-based compensation	479,137	-
Accretion of convertible debenture	159,191	40,314
Transaction cost	2,351,562	-
Accrued interest expense on convertible debenture	28,996	149,902
Loss on conversion of convertible debentures	886,643	-
Realized loss (gain) on sale of investment	769,180	(82,996)
Fair value change in investments	(7,701,177)	(714,787)
	(681,630)	(100,778)
Changes in non-cash working capital items:		
Amounts receivable	(28,362)	-
Accounts payable and accrued liabilities	91,906	5,938
Net cash used in operating activities	(618,086)	(94,840)
Investing activities		
Acquisition of investments	(27,500,000)	(200,100)
Proceeds from sale of investments	22,291,020	275,820
Net cash provided by (used in) investing activities	(5,208,980)	75,720
Financing activities		
Private placement, net	8,491,125	-
Warrant exercise	311,540	-
Option exercise	63,000	-
Repayment of interest on convertible loans	(436,030)	-
Net cash provided by investing activities	8,429,635	-
Net increase (decrease) in cash	2,602,569	(19,120)
Cash, beginning of the period	1,933	39,753
Cash, end of the period	\$ 2,604,502	\$ 20,633

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

1. NATURE OF OPERATIONS AND GOING CONCERN

Organic Flower Investments Group Inc. (formerly Q Investments Ltd). (the “Company”) was incorporated under the *Company Act* of British Columbia. On January 19, 2001, the Company received its certificate of continuance from the Bermuda Monetary Authority in accordance with section 132C (4) (d) of the *Companies Act 1981* of Bermuda. On December 6, 2018, the Company domiciled its operations to British Columbia, Canada. The Company’s common shares are listed on the Canadian Securities Exchange under the trading symbol SOW, on the OTC Markets under the symbol QILFF and on the Frankfurt Stock Exchange under the ticker symbol 2K6

The Company is an investment holding firm, which specializes in providing early-stage financing to private and public companies.

The head office, principal and registered address, and the records of the Company are located at 810-789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

These condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes the Company will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Several adverse conditions cast doubt on the validity of this assumption. The Company has an accumulated deficit of \$26,893,653 (June 30, 2018 - \$29,238,491), limited resources, no source of operating cash flow and no assurance that sufficient funding will be available. Management has the option to raise funds through a combination of equity and/or debt financing, along with a sale of investments. The success of these plans will depend upon future events, and the Company’s ability to achieve profitability and positive cash flows is uncertain. These material uncertainties cast significant doubt upon the Company’s ability to continue as a going concern.

These condensed interim consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary, should the Company be unable to continue as a going concern. Such amounts could be material.

2. BASIS OF PREPARATION

a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board.

The Board of Directors approved these condensed interim consolidated financial statements on May 30, 2019.

b) Basis of presentation

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34 – Interim Financial Reporting. These condensed interim consolidated financial statements do not include all of the information required for annual financial statements and should be read in conjunction with the Company’s audited consolidated financial statements for the year ended June 30, 2018. These financial statements have been prepared following the same accounting policies as the Company’s audited consolidated financial statements for the year ended June 30, 2018.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

2. BASIS OF PREPARATION (CONTINUED)

Basis of measurement

These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments, which are measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

Functional and presentation currency

During the period ended March 31, 2019, the Company changed its presentation currency from US dollars to the Canadian dollars to better reflect the Company's ongoing transactions (note 12). The functional currency of the Company and each of its subsidiaries is the Canadian dollar.

Basis of consolidation

(i) Subsidiaries

Subsidiaries are entities controlled by the Company. Control exists when the Company is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power over the subsidiaries. In assessing control, potential voting rights that currently are exercisable are taken into account. The accounts of the Company's wholly owned subsidiaries, Cubix Acquisitionco Inc., incorporated in British Columbia on July 3, 2001, Pleasant Shores Ventures Ltd., incorporated in British Virgin Islands on May 15, 2006, and 1180782 B.C. Ltd. d/b/a Delta Organic Cannabis ("DOC"), incorporated in British Columbia on September 25, 2018 are included in the consolidated financial statements from the date control commenced until the date control ceases.

(ii) Transactions eliminated on consolidation

Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed interim consolidated financial statements.

3. SIGNIFICANT ACCOUNTING POLICIES

In preparing these condensed interim consolidated financial statements, the significant accounting policies and the significant judgments made by management in applying the Company's significant accounting policies and key sources of estimation uncertainty were the same as those that applied to the Company's audited consolidated financial statements for the year ended June 30, 2018, with exception to the new accounting standards adopted by the Company discussed below.

The preparation of condensed interim consolidated financial statements requires that the Company's management make judgments and estimates of effects of uncertain future events on the carrying amounts of the Company's assets and liabilities at the end of the reporting period. Actual future outcomes could differ from present estimates and judgments, potentially having material future effects on the Company's condensed interim financial statements. Estimates are reviewed on an ongoing basis and are based on historical experience and other facts and circumstances. Revisions to estimates and the resulting effects on the carrying amounts of the Company's assets and liabilities are accounted for prospectively.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

3. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Share Capital

During the period ended March 31, 2019, the Company adopted a share structure consisting of unlimited common shares with no par value.

IFRS 9 – Financial Instruments

IFRS 9 was issued by the International Accounting Standards Board ("IASB") in November 2009 and October 2010 and replaced IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Two measurement categories continue to exist to account for financial liabilities in IFRS 9, FVTPL and amortized cost. Financial liabilities held-for-trading are measured at FVTPL, and all other financial liabilities are measured at amortized cost unless the fair value option is applied. The treatment of embedded derivatives under the new standard is consistent with IAS 39 and is applied to financial liabilities and non-derivative hosts not within the scope of the standard. IFRS 9 introduces an 'expected credit loss' model for the impairment of financial assets. The measurement of the Company's financial assets and liabilities will not significantly change on transition to IFRS 9. Additionally, the Company is exposed to minimal expected credit losses due to the fact that it has an insignificant amount of accounts receivable. The Company has adopted the amendments to IFRS 9 in its financial statements for the annual period beginning on July 1, 2018 with no resulting adjustments.

IFRS 15 – Revenue with Contracts

IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It has replaced IAS 18 Revenue, IAS 11 Construction Contracts and related interpretations. The new standard establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer.

The Company has adopted the amendments to IFRS 15 in its financial statements for the annual period beginning on July 1, 2018 with no resulting adjustments.

Changes in accounting standards

The following is an overview of new accounting standards that the Company will be required to adopt in future years. The Company does not expect to adopt any of these standards before their effective dates. The Company does not expect that the adoption of IFRS 15 will have a material impact on its condensed interim consolidated financial statements and will continue to evaluate the impact of IFRS 16 and the amendment to IFRS 11 on its condensed interim consolidated financial statements.

Accounting for Acquisitions of Interests in Joint Operations (Amendments to IFRS 11 *Joint Arrangements*)

Amends IFRS 11 to require an acquirer of an interest in a joint operation in which the activity constitutes a business (as defined in IFRS 3 *Business Combinations*) to:

- apply all of the business combinations accounting principles in IFRS 3 and other IFRS, except for those principles that conflict with the guidance in IFRS 11.
- disclose the information required by IFRS 3 and other IFRS for business combinations.

The amendments apply both to the initial acquisition of an interest in joint operation, and the acquisition of an additional interest in a joint operation (in the latter case, previously held interests are not remeasured).

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

3. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Accounting for Acquisitions of Interests in Joint Operations (Amendments to IFRS 11 *Joint Arrangements*) (Continued)

Note: The amendments apply prospectively to acquisitions of interests in joint operations in which the activities of the joint operations constitute businesses, as defined in IFRS 3, for those acquisitions occurring from the beginning of the first period in which the amendments apply. Amounts recognized for acquisitions of interests in joint operations occurring in prior periods are not adjusted.

Applicable to the Company's annual period beginning July 1, 2018.

IFRS 16 *Leases*

This new standard sets out the principles for the recognition, measurement, presentation and disclosure of leases for both the lessee and the lessor. The new standard introduces a single lessee accounting model that requires the recognition of all assets and liabilities arising from a lease.

The main features of the new standard are as follows:

- An entity identifies as a lease a contract that conveys the right to control the use of an identified asset for a period of time in exchange for consideration.
- A lessee recognizes an asset representing the right to use the leased asset, and a liability for its obligation to make lease payments. Exceptions are permitted for short-term leases and leases of low-value assets.
- A lease asset is initially measured at cost, and is then depreciated similarly to property, plant and equipment. A lease liability is initially measured at the present value of the unpaid lease payments.
- A lessee presents interest expense on a lease liability separately from depreciation of a lease asset in the statement of profit or loss and other comprehensive income.
- A lessor continues to classify its leases as operating leases or finance leases, and to account for them accordingly.
-
- A lessor provides enhanced disclosures about its risk exposure, particularly exposure to residual-value risk.

The new standard supersedes the requirements in IAS 17 Leases, IFRIC 4 Determining Whether an Arrangement Contains a Lease, SIC-15 Operating Leases – Incentives and SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease.

Applicable to the Company's annual period beginning July 1, 2019.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

4. FINANCIAL INSTRUMENTS

The Company classifies its financial instruments into categories as follows: cash and investments, as financial assets at FVTPL; convertible debenture and accounts payable and accrued liabilities, as other financial liabilities.

Fair value

Cash and investments, consisting of marketable securities, are carried at fair market value based on quoted market prices in an active market. The carrying values of accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these financial instruments.

Convertible debenture issued on June 16, 2016 was initially valued under Level 3 of the fair value hierarchy using a discount rate of 17%, which was based on similar debt for comparable companies. Subsequent measurement is carried at amortized cost. As at March 31, 2019, the principal and accrued interest is \$Nil (2018 - \$1,579,095).

The Company's measurement of the fair value of financial instruments as at March 31, 2019 and June 30, 2018 in accordance with the fair value hierarchy is as follows:

	Total	Level 1	Level 2	Level 3
March 31, 2019				
Cash	\$ 2,604,502	\$ 2,604,502	\$ -	\$ -
Investments	\$ 49,584,888	\$ 587,923	\$ -	\$ 48,996,965
June 30, 2018				
Cash	\$ 1,933	\$ 1,933	\$ -	\$ -
Investments	\$ 1,296,791	\$ 1,296,791	\$ -	\$ -

5. FINANCIAL RISK MANAGEMENT

(a) Overview

The Company has exposure to the following risks from its use of financial instruments:

- Market risk;
- Credit risk; and
- Liquidity risk.

(b) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: interest rate risk, foreign currency risk and other price risk.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

5. FINANCIAL RISK MANAGEMENT (CONTINUED)

(i) Interest rate risk

The Company's cash is held in bank accounts, which have nominal interest rates attached to them; therefore, fluctuations in market interest rates would not have a material impact on their fair market values as at March 31, 2019 and June 30, 2018.

The Company's convertible debentures have fixed interest rates of 15% per annum. During the period ended March 31, 2019, the Company converted all of its convertible debt. As at March 31, 2019, the principal and accrued interest is \$Nil (2018 - \$1,579,095). As such, the Company's cash flow would not be impacted by changes in market rates of interest.

(ii) Foreign currency risk

The Company is exposed to financial risk related to the fluctuation of foreign exchange rates. The Company's functional currency is the Canadian dollar and the condensed interim consolidated financial statements are presented in Canadian dollars. The Company is not exposed to significant foreign currency risk.

(ii) Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk and foreign currency risk. The Company holds certain marketable securities that will fluctuate in value as a result of fluctuations in current market prices of those securities. Furthermore, as the Company's marketable securities are resource exploration and cannabis companies, market values will fluctuate subject to the price of cannabis and its derivatives, commodity prices, economic cycles and political events. Based upon the Company's investment portfolio at March 31, 2019, a 96% (2018 - 96%) increase or decrease in the market price of the securities held would result in an increase/decrease to net income (loss) and comprehensive income (loss) of approximately \$ 4,900,000 (2018 - \$1,801,000).

(c) Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its payment obligations. The Company's exposure to credit risk is limited to its cash balances. The risk exposure is limited to the carrying amounts at the statement of financial position dates.

The Company's cash balances are held in accounts at a major Canadian financial institution. The credit risk associated with cash is mitigated, as cash is held at major institutions with high credit ratings.

Concentration of credit risk and maximum exposure thereto exists as follows:

	March 31, 2019	June 30, 2018
Cash	\$ 2,604,502	\$ 1,933

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

5. FINANCIAL RISK MANAGEMENT (CONTINUED)

(d) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company assesses its liquidity risk by forecasting cash flows required by operations and anticipated financing activities.

The Company has a cash balance at March 31, 2019 of \$2,604,502 (2018 - \$1,933) and investments with a fair value of \$49,584,888 (2018 - \$1,296,791). At March 31, 2019, the Company has accounts payable and accrued liabilities of \$137,325 (2018 - \$45,417). As at March 31, 2019, the Company has working capital of \$52,080,427 (2018 - \$ 1,253,307). The Company relies upon financing to maintain sufficient working capital. There is no assurance that such financing will be available on terms and conditions acceptable to the Company.

The Company's accounts payable and accrued liabilities are due in the short-term (0 to 3 months).

6. CAPITAL MANAGEMENT

The Company considers its capital structure to include all components of shareholders' equity (deficiency). Management's objective is to ensure there is sufficient capital to minimize liquidity risk and to continue as a going concern. Management reviews its capital management approach on an ongoing basis and believes its approach, given the relative size of the Company, is reasonable.

Although the Company has been successful in the past in obtaining financing through the sale of equity securities, there can be no assurance that the Company will be able to obtain adequate financing in the future or that the terms of such financing will be acceptable to the Company.

The Board of Directors does not establish a quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company's share capital is not subject to any externally imposed capital requirements and the Company did not change its approach to capital management during the period ended March 31, 2019.

7. INVESTMENTS

Investments consist of common shares held at fair market value as follows:

March 31, 2019	
Bucking Horse Energy Inc. (3,414,700 common shares)	\$ -
Pinedale Energy Limited (3,777,000 common shares)	396,585
Pinedale Energy Limited (3,487,000 warrants)	190,855
San Angelo Oil Limited (5,000 common shares)	-
Agraflora Organics International Inc. (44,582,040 common shares)	28,410,485
Agraflora Organics International Inc. (10% Earn-In)	20,586,919
Ultra Petroleum Corp. (45 common shares)	44
Total Investments	\$ 49,584,888
June 30, 2018	
Bucking Horse Energy Inc. (3,414,700 common shares)	\$ -
Pinedale Energy Limited (3,777,000 common shares)	793,170
Pinedale Energy Limited (3,487,000 warrants)	503,517
San Angelo Oil Limited (5,000 common shares)	-
Ultra Petroleum Corp. (45 common shares)	104
Total Investments	\$ 1,296,791

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

7. INVESTMENTS (CONTINUED)

On December 7, 2018, the Company acquired 7,500,000 common shares of DOC for \$7,500,000. DOC is a privately held Toronto-based cannabis investment Company. DOC's sole asset is an equity participation and earn-in agreement with Agraflora Organics International Inc. ("Agraflora"), a growth oriented and diversified international cannabis Company. Agraflora is developing a large scale 2.2 million square foot commercial medical cannabis cultivation operation ("Facility") in Delta, British Columbia. In addition to the equity interest in Agraflora, DOC will earn a 20% interest in the Facility. To date, DOC has acquired 27,863,775 common shares of Agraflora.

On March 18, 2019, the Company closed the acquisition (the "Acquisition") of all of the issued and outstanding shares of DOC that it did not otherwise own, in consideration of the issuance of an aggregate of 54,687,503 units of the Company ("Units"). Each Unit consists of one common share of OFIG and one common share purchase warrant ("Warrant") that is exercisable to purchase an additional common share of OFIG at a price of \$0.65 until December 5, 2020.

DOC's sole asset is an equity participation and earn-in agreement (the "Agreement") with Agraflora.

In connection with the Company's acquisition of DOC, it has acquired control and direction of 44,582,040 common shares of Agraflora. Immediately before the Acquisition, the Company held nil common shares of Agraflora. Immediately after the Acquisition, the Company had control and direction of 44,582,040 common shares of Agraflora, representing approximately 11.2% of the outstanding common shares of Agraflora on a non-diluted basis and 10% of the earn in interest in the Facility. The Company acquired control and direction over the common shares in connection with the Acquisition of DOC and for investment purposes.

The acquisition has been accounted for by the Company as a purchase of assets and assumption of liabilities. The acquisition did not qualify as a business combination under *IFRS 3 – Business Combinations*, as the significant inputs, processes and outputs, that together constitute a business, do not currently exist.

The purchase price was determined based on *IFRS 2 - Share Based Payments* and allocated as follows:

Purchase Price:	\$
Cash	7,500,000
54,687,503 common shares issued at \$0.43 per share	23,515,626
Black-Scholes calculation on warrants issued	12,631,493
Total	43,647,119
Net Assets Acquired:	
Shares in Agraflora at fair value	23,060,200
Earned Interest in Agraflora's Facility	20,586,919
Total	43,647,119

The earned interest in Agraflora's Facility was calculated based on a residual allocation of the total purchase price and is fair valued under Level 3.

During the period ended March 31, 2019, the Company recognized unrealized income on fair value of investments of \$7,701,177 (2018 – \$ 714,787). During the period ended March 31, 2019, the Company sold 44,582,040 for net proceeds of 22,291,020 and realized an accounting loss of \$769,180.

During the period ended March 31, 2018, the Company sold 140,000 shares of Pentanova Energy Corp for net proceeds of \$56,489 and realized a loss of \$16,676 on the sale, 60,000 shares of Leagold Mining Corp. for net proceeds of \$182,108 and realized a gain of \$77,108, 114,000 shares of Cabral Gold Inc. for net proceeds of \$34,407 and a realized gain of \$31,557 and 30,000 shares of Oronova for net proceeds of \$2,815 and a realized loss of \$8,993.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

8. CONVERTIBLE DEBENTURES

During the period ended March 31, 2019, the Company converted \$1,331,250 of the principal portion of the convertible debt by issuing 13,312,500 Units at a deemed value of \$0.10 per Unit. The Company repaid accrued interest of \$436,030. The fair value of the shares on the date of the conversion was \$3,727,500 and the Company recognized a loss on conversion of convertible debenture of \$886,643.

The following table reconciles the recorded value of the liability and the equity components of the convertible debentures:

	Liability \$	Equity \$	Total \$
Balance, June 30, 2017	1,325,705	1,509,607	2,835,312
Interest expense	149,902	-	149,902
Accretion	40,314	-	40,314
Balance, March 31, 2018	1,515,921	1,509,607	3,025,528
Balance, June 30, 2018	1,579,093	1,509,607	3,088,700
Interest expense	28,996	-	28,996
Accretion	159,191	-	159,191
Conversion	(1,331,250)	(1,509,607)	(2,840,857)
Interest paid	(436,030)	-	(436,030)
Balance, March 31, 2019	-	-	-

On June 16, 2016, the Company completed its secured convertible debenture financing raising \$1,000,000. In addition, the Company completed a demand loan conversion by converting demand loans in the aggregate amount of \$331,250 into secured convertible debenture for the same amount.

The secured convertible debentures accrued interest at 15% per annum, have a maturity date of June 16, 2021, and the principal amount of the debentures were convertible into units at \$0.10 per Unit prior to the maturity date. Each Unit is comprised one common share of the Company and one transferable common share purchase Warrant. Each Warrant entitles the holder to purchase one common share of the Company at a price of \$0.10 until June 16, 2021. The holders of the debentures had the right to convert interest on the debentures into common shares at market price at the time the interest became due and payable.

For the convertible debentures issued for cash of \$1,000,000, management estimated that the fair value of the debt using a discount rate of 17% applicable to the Company's business, with the residual value allocated to the conversion feature. For the \$331,250 convertible debentures that satisfied the extinguishment of loans payable (Note 9), management determined the fair value using a net present value calculation, and the conversion feature was valued using a Black-Scholes option pricing model. The convertible notes are being accreted to the face value of the debt plus interest to maturity.

9. SHARE CAPITAL

(a) Authorized

Unlimited common shares with no par value.

(b) Issued and fully paid

As at March 31, 2019, the Company had 175,340,141 shares issued and outstanding. As at June 30, 2018 the Company had 6,120,190 shares issued and outstanding.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

9. SHARE CAPITAL (CONTINUED)

(b) Issued and fully paid (Continued)

On March 18, 2019, the Company closed the Acquisition of all of the issued and outstanding shares of DOC that it did not otherwise own, in consideration of the issuance of an aggregate of 54,687,503 Units of the Company with a fair value of \$23,513,626. Each Unit consists of one common share of OFIG and one common share purchase Warrant that is exercisable into one common share of OFIG at a price of \$0.65 until December 5, 2020. DOC's sole asset is an equity participation and earn-in Agreement with Agra.

In connection with the Acquisition, the Company issued 5,468,770 common shares with a fair value of \$2,351,563, which has been recorded to transaction costs.

During the period ended March 31, 2019, the Company approved a forward stock split ("Stock Split") of its issued share capital on a one old for two new basis. The Stock Split has been reflected retroactively.

On December 12, 2018, the Company issued 17,898,766 Units pursuant to a private placement at a price of \$0.30 per Unit for gross proceeds of \$5,369,630. Each Unit consists of one common share and one Warrant; each Warrant is exercisable at \$0.65 per share for 2 years. The Company paid legal and share issuance costs of \$291,730.

On August 21, 2018, the Company issued 59,360,424 Units pursuant to a private placement at a price of \$0.0575 per Unit for gross proceeds of \$3,413,226. Each Unit consists of one common share and one warrant; each Warrant is exercisable at \$0.075 per share for five years.

On August 21, 2018, the Company issued 26,625,000 Units pursuant to the conversion of the principal portion of the Company's outstanding convertible debenture. Each Unit consists of one common share and one Warrant; each Warrant is exercisable at \$0.05 per share until June 16, 2021.

During the period ended March 31, 2019, the Company issued 4,819,488 common shares pursuant to Warrant exercises for gross proceeds of \$311,540.

During the period ended March 31, 2019, the Company issued 360,000 common shares pursuant to option exercises, for gross proceeds of \$63,000. The Company reclassified \$46,989 from contributed surplus to share premium.

During the period ended March 31, 2018, the Company did not issue any common shares.

ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)

9. SHARE CAPITAL (CONTINUED)

(c) Common share purchase warrants

A continuity schedule of the Company's Warrants is as follows:

	Number of share purchase warrants #	Weighted average exercise price \$
Outstanding, June 30, 2017 and 2018	-	
Granted during the period	158,985,913	0.33
Exercised during the period	(4,819,488)	(0.07)
Outstanding, March 31, 2019	153,866,425	0.11

As of March 31, 2019, the Company had Warrants outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise Price \$	Number of Warrants
June 16, 2021	0.05	24,628,140
August 21, 2023	0.075	56,537,816
December 5, 2020	0.65	18,012,966
December 5, 2020	0.65	54,687,503
		153,866,425

(d) Stock option plan

The Company has implemented a rolling stock option plan whereby a maximum of 10% of the issued shares will be reserved for issuance under the Plan. The Board may, from time to time, designate any director, officer, employee or consultant of the Company or of any affiliates to whom options shall be granted and the number of shares to be optioned based on:

- (i) The number of shares in respect of which options, including prior options, may be outstanding at any time should not exceed 10% of the outstanding shares at that time. In any twelve-month period, no one may receive options or prior options exceeding 5% of the outstanding shares. In any twelve-month period, the total number of options granted to all insiders of the Company may not exceed 10% of the outstanding shares. In any twelve-month period, no one consultant may receive options or prior options on a number of shares that taken together exceeds 2% of the outstanding shares, except as permitted by the policies of the Exchange. Options issued to consultants performing investor relations activities must vest in stages over a minimum period of twelve months with no more than 25% of the options vesting in any three-month period.
- (ii) The option price will be decided by the Board and shall not be less than the fair market value of the shares.
- (iii) The option term will be such period as may be determined by the Board, but subject to the policies of the Exchange, presently restricted to ten years. The Board may, with the permission of the holder of the option, cancel any outstanding options.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

9. SHARE CAPITAL (CONTINUED)

(d) Stock option plan (continued)

On March 6, 2019, the Company granted 1,000,000 stock options to a consultant of the Company with an exercise price of \$0.45 and with a term of 5 years. \$Nil value has been assigned to those options.

On September 20, 2018, the Company granted 3,564,112 stock options to various consultants of the Company with an exercise price of \$0.16 and with a term of 10 years. The estimated fair value of the stock options was \$479,137, measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - \$0.14; exercise price - \$0.16; expected life - 10 years, volatility - 128.77%, dividend yield - \$0; and risk-free rate - 2.42%.

During the period ended March 31, 2018, the Company did not issue any stock options.

A continuity schedule of the Company's stock option is as follows:

	Number of share purchase options #	Weighted average exercise price \$
Outstanding, June 30, 2017 and 2018	600,000	0.18
Granted during the period	4,564,112	0.16
Exercised during the period	(360,000)	(0.18)
Outstanding, March 31, 2019	4,804,112	0.16

As of March 31, 2019, the Company had stock options outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise Price \$	Number of options
July 4, 2021	0.175	240,000
March 6, 2024	0.45	1,000,000
September 20, 2028	0.16	3,564,112
		4,804,112

10. RELATED PARTY TRANSACTIONS

The following is a summary of related party transactions that occurred during the period ended March 31, 2019:

- (a) Included in accounts payable and accrued liabilities is \$38,200 (June 30, 2018 - \$13,261) payable to officers and directors of the Company. Amounts due to related parties have no stated terms of interest and/or repayment.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

10. RELATED PARTY TRANSACTIONS (CONTINUED)

- (b) Key management personnel include the directors and officers of the Company. Key management compensation consists of the following:

	March 31, 2019 \$	March 31, 2018 \$
Management and administrative fees paid or accrued to a company controlled by the CFO	12,208	19,341
Management and administrative fees paid or accrued to a company controlled by the President	14,130	-
Consulting fees paid or accrued to a company controlled by Joel Dumaresq	25,000	-
Consulting fees paid or accrued to a company controlled by Theo Van Der Linde	28,000	-
Management and administrative fees paid to a company controlled by the former President	7,500	22,500

There were no post-employment benefits, termination benefits or other long-term benefits paid to key management personnel for the period ended March 31, 2019 and 2018.

11. SEGMENTED DISCLOSURE

Management has determined that the Company operates in one dominant industry segment, which involves taking early equity and/or debt positions. Substantially all of the Company's operations are located in Canada.

12. CHANGE IN PRESENTATION CURRENCY

Prior to July 1, 2018, the Company presented its annual and quarterly consolidated statements of financial position, loss and comprehensive loss, shareholders' equity (deficiency) and cash flows in United States dollars. Effective July 1, 2018, the Company changed its presentation currency to the Canadian dollar to facilitate the comparability of the Company's financial information with similar Canadian companies. The Company's consolidated financial statements for all periods presented have been translated back to Canadian dollars, and appropriately restated.

All previously recorded exchange differences arising from translating Canadian dollar functional currency consolidated financial statements to the previously utilized US dollar presentation currency had been recorded in other comprehensive income or loss as foreign currency translation adjustments. All comparative financial information has been restated to reflect the Company's results as if they had been historically reported in Canadian dollars, including writing off the previously recognized other comprehensive income of \$1,235,930 as at June 30, 2018 (July 1, 2017 - \$1,239,212) against deficit.

As the Company's functional currency and presentation currency are now both the Canadian dollar, the Company has accounted for exchange differences arising on foreign currency denominated transactions and balances in accordance with International Accounting Standard 21, The Effects of Changes in Foreign Exchange Rates. As such, foreign currency denominated transactions in the consolidated statements of loss and cash flows for each period have been translated into the presentation currency using the average exchange rate prevailing during each reporting period. All assets and liabilities have been translated using the exchange rate prevailing at the consolidated statements of financial position dates. Equity transactions have been translated at the exchange rate in effect on the date of the specific transaction. Any foreign currency translation differences from foreign currency denominated transactions are recorded in profit and loss.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

13. SUBSEQUENT EVENTS

On April 22, 2019, the Company entered into a binding letter of intent to acquire 80% of Potluck Potions and Edibles Inc. ("Potluck"). Potluck specializes in the management of beverage industry supply chains, including the bottling and manufacturing of a variety of beverages. Under the terms of the agreement, the Company will issue 10 million common shares upon execution of the definitive supply and distribution agreement and up to 6 million common shares upon the achievement of certain milestones.

On April 26, 2019, the Company entered into a definitive agreement ("Purchase Agreement") to acquire 80% interest in the Edibles and Infusions Corporation ("Edibles and Infusions"). Upon execution of the Purchase Agreement, the Company conceived a joint-venture ("JV") with one of North America's largest and most storied manufacturer and distributor of chocolate and confectionary products.

As consideration, the Company will issue or pay the following:

- \$10 million at closing, comprised of common shares of the Company (20,000,000 common shares issued subsequently);
- Up to \$32.5 million common shares of the Company at an attributed price equal to a 5 day VWAP at the time of issuance, upon the JV achieving certain milestones throughout 2022;
- Fund up to \$15 million to develop a facility; and
- \$9 million common shares to the manager of the JV based on certain milestones.

The Company also acquired an option ("Option") to purchase certain business assets of Edibles and Infusions for the purchase price of \$12.5 million.

As consideration, the Company will issue:

- \$1 million for the option to be exercisable within 6 months of the Option grant (2,485,726 common shares issued subsequently); and,
- An additional \$1 million of the Company to extend the exercise period by 6 months.

The Company issued 2,000,000 common shares to arm's length parties in connection with the acquisition of Edibles and Infusions.

On May 6, 2019, the Company issued 1,000,000 stock options to an arm's length consultant with an exercise price of \$0.45 and expires in 5 years from the date of grant.

On May 7, 2019, the Company entered into a definitive agreement to acquire 80% of 11353675 Canada Corp, d/b/a CanaBeer ("CanaBeer"). CanaBeer holds claim to an exclusive formulation, manufacturing and distribution rights for all cannabinoid-infused beverages developed at a leading Toronto-based brewery.

As consideration, the Company will issue 9,166,000 common shares of the company, based on the five-day VWAP of the Company's common shares for the five trading sessions prior to the announcement of the definitive agreement. A finder's fee is payable on this transaction.

On May 8, 2019, the Company entered into a distribution and cannabis processing/finishing agreement (the "Downstream Agreement") with ICC International Cannabis Corp. ("ICC"). ICC will permit the Company access to its European distribution network, comprised of 80,000 retail outlets and pharmacies and grant the Company commercial rights for cannabis processing/finishing at its EU-GMP certified facilities.

**ORGANIC FLOWER INVESTMENTS GROUP INC.
(FORMERLY Q INVESTMENTS LTD.)
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2019 AND 2018
(Unaudited - Expressed in Canadian Dollars)**

13. SUBSEQUENT EVENTS (CONTINUED)

On May 13, 2019, ICC and the Company entered into a definitive agreement with Toronto Wolfpack RLFC ("Toronto Wolfpack") and HowlBrands to manufacture and distribute a suite of athlete-focused, cannabidiol performance products. Under the terms of the agreement, the Company issued 6,725,239 common shares.

On May 17, 2019, the Company issued 15,290,000 stock options to arm's length parties with an exercise price of \$0.325 and expires in 5 years from the date of grant.

On May 22, 2019, the Company entered into a binding Letter of Intent ("LOI") to sell to AgraFlora 100% of the Company's assets, which includes: the Company's 20% interest in the Delta Greenhouse Complex, a number of product formulation operations and the rights to an trans-European distribution network. Under the terms of the LOI, the sale price for the assets will be comprised of 1.15 shares of Agraflora for each one issued and outstanding share of the Company at the time of closing.

In May 2019, the Company entered into two definitive agreements to acquire 80% of Canada Cannabis Therapeutics Company ("CCTC") and Colorado Science Company ("Colorado Science") by issuing 5 million common shares to the shareholders of CCTC and another 5 million shares to the shareholders of Colorado Science. Colorado Science holds claim to a number of cannabinoid product formulations equipped with patented micro-diffusion technology.

Subsequent to period end, the Company issued 1,300,000 common shares pursuant to Warrants exercised for gross proceeds of \$97,500.

APPENDIX B

ORGANIC FLOWER INVESTMENTS GROUP INC.

Management's Discussion & Analysis for the nine month period ended March 31, 2019

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)

Management Discussion and Analysis
For the period ended March 31, 2019 and 2018
(Expressed in Canadian Dollars)

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)
Management's Discussion and Analysis
March 31, 2019 and 2018

The following management's discussion and analysis ("MD&A") for Organic Flower Investments Group Inc. (formerly Q Investments Ltd.) was prepared by management based on information available as at May 30, 2019. This MD&A should be reviewed in conjunction with the condensed interim consolidated financial statements (the "**Interim Financial Statements**") and notes thereto, for the period ended March 31, 2019. The Company's condensed interim consolidated financial statements are filed on SEDAR and available for review at www.sedar.com.

As used in this MD&A, the terms "we", "us", "our", "Organic Flower", "OFIG" and the "Company" means Organic Flower Investments Group Inc. (formerly Q Investments Ltd.), and our wholly-owned subsidiaries: Cubix Acquisitionco Inc., Pleasant Shores Ventures Ltd. and 1180782 B.C. Ltd. d/b/a Delta Organic Cannabis.

During the period ended March 31, 2019, the Company changed its presentation currency from US dollars to the Canadian dollars to better reflect the Company's ongoing transactions. Unless otherwise noted, all dollar amounts are expressed in Canadian dollars and any references to common shares are to common shares in the capital of Q Investments, unless the context clearly states otherwise.

Forward-Looking Information

Certain information in this MD&A and the documents incorporated by reference contain forward-looking information, which includes forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements are statements which relate to future events or our future performance, including our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", or "potential" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause the Company's or the industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. No assurance can be given that any of the events anticipated by the forward-looking information and statements will occur or, if they do occur, what benefits we will obtain from them. This MD&A contains forward-looking information and statements, which may include, but are not limited to: statements with respect to the financial and operating performance of the Company and its subsidiaries; investment objectives and strategies; business goals and strategies; forecast operating and financial results; planned capital expenditures; competitive advantages; business prospects and opportunities; proposed transactions and subsequent events; costs and timing of developmental new projects; our management's assessment of future plans and operations; our anticipated liquidity and various matters that may impact such liquidity; and requirements for additional capital.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgement regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this MD&A. These assumptions, which includes management's current expectations, estimates and assumptions about certain projects and the markets we operate in, the global economic environment, interest rates; our ability to generate sufficient cash flow from operations to meet our current and future obligations and other risks and uncertainties described from time to time in the filings we make with securities regulatory authorities; the impact of increasing competition; our ability to obtain qualified staff; currency, exchange and interest rates. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking information and statements, including, but not limited to: the failure of the Company to execute our business plans; general economic conditions as they affect us; risks associated with technology and its application to our business; changes in the applicable regulatory framework, including changes to tax and other laws or regulations, or changes associated with compliance; our ability to control our operating costs, general administrative and other expenses; other factors beyond our control; insufficient investor interest in our securities which may impact on our ability to raise additional financing as required; and those factors described in the section titled "Risk Factors" in this MD&A.

Forward-Looking Information (continued)

This forward-looking information is based on the estimates and opinions of our management at the time they are made. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Readers of this MD&A are cautioned not to rely on such forward-looking statements. The forward-looking information and statements contained in this MD&A are made as of May 30, 2019 and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law or applicable regulation.

Description of Business

The Company is an investment holding firm, which specializes in providing early-stage financing to private and public companies. Our management's primary objective is to identify and secure innovative investment opportunities, which will add to the equity value for our shareholders.

Leveraging strategic relationships, proprietary investments and exclusive partnerships with preeminent international cannabis cultivators and formulators for the development of best in class products and brands to be marketed and distributed throughout our global footprint.

Overall Performance

Management has determined that the Company operates in one dominant industry segment, which involves taking early equity and/or debt positions, primarily in promising, early-stage companies. On December 6, 2018, the Company domiciled its operations to British Columbia, Canada. As at March 31, 2019, the Company had a working capital of \$52,080,427 compared to working capital of \$1,253,307 at June 30, 2018. As at March 31, 2019, cash was \$2,604,502 compared to \$1,933 at June 30, 2018. The Company posted a net income of \$2,344,838 for the period ended March 31, 2019 compared to a net loss of \$506,789 for the comparative period.

The Interim Financial Statements of the Company have been prepared on the basis of accounting principles applicable to a going concern, which assumes the Company will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Several adverse conditions cast doubt on the validity of this assumption. The Company has limited resources, limited sources of operating cash flow and if required, no assurances that sufficient funding will be available.

Certain economic conditions are causing volatile natural resources prices, which may negatively impact the Company's investments. Management cannot predict the timing or duration of the current economic situation or the strength of any subsequent industry recovery and cannot predict the extent to which the current volatility will impact the Company.

Corporate Highlights – Equity Transactions

During the period ended March 31, 2019, the Company approved a forward stock split ("Stock Split") of its issued share capital on a one old for two new basis. The Stock Split has been reflected retroactively.

On August 21, 2018, the Company issued 59,360,424 units ("Units") at a price of \$0.0575 per Unit for gross proceeds of \$3,413,224. Each Unit consist of one common share and one share purchase warrant (a "Warrant"); each Warrant is exercisable at \$0.075 per common share for five years.

On August 21, 2018, the Company issued 26,625,000 Units pursuant to the conversion of the principal portion of the Company's outstanding convertible debenture. Each Unit consists of one common share and one Warrant; each Warrant is exercisable at \$0.05 per common share until June 16, 2021.

Corporate Highlights – Equity Transactions (continued)

During the period ended March 31, 2019, the Company issued 4,819,488 common shares pursuant to Warrant exercises for gross proceeds of \$311,540.

During the period ended March 31, 2019, the Company issued 360,000 common shares pursuant to option exercises for gross proceeds of \$63,000. The Company reclassified \$46,989 from contributed surplus to share premium.

On December 6, 2018, the Company redomiciled its operations from Bermuda to British Columbia, Canada.

On December 12, 2018, the Company issued 17,898,766 Units at a price of \$0.30 per Unit for gross proceeds of \$5,369,630. Each Unit consists of one common share and one Warrant; each Warrant is exercisable at \$0.65 per share for 2 years. In conjunction with the Unit financing, the Company paid legal and share issuance costs of \$291,730.

On March 18, 2019, the Company closed the Acquisition of all of the issued and outstanding shares of 1180782 B.C. Ltd. d/b/a Delta Organic Cannabis ("DOC") that it did not otherwise own, in consideration of the issuance of an aggregate of 54,687,503 Units of the Company with a fair value of \$23,513,626. Each Unit consists of one common share of OFIG and one Warrant that is exercisable into one common share of OFIG at a price of \$0.65 until December 5, 2020. DOC's sole asset is an equity participation and earn-in Agreement with Agraflora.

Corporate Highlights – Operations

Effective January 23, 2019, the Company's common shares commenced trading on the Canadian Securities Exchange and Frankfurt Stock Exchange under its existing symbol "SOW" and "2K6," respectively. The Company's common shares were voluntarily delisted from the TSX Venture Exchange.

Delta Organic Cannabis ("DOC")

On December 7, 2018, the Company acquired 7,500,000 common shares of DOC for \$7,500,000. DOC is a privately held Toronto-based cannabis investment Company. DOC's sole asset is an equity participation and earn-in agreement with Agraflora Organics International Inc. ("Agraflora"), a growth oriented and diversified international cannabis Company. Agraflora is developing a large scale 2.2 million square foot commercial medical cannabis cultivation operation ("Facility") in Delta, British Columbia. In addition to the equity interest in Agraflora, DOC will earn a 20% interest in the Facility.

To Date, DOC has advanced \$40,000,000 for 89,704,080 common shares of Agraflora. Agraflora is a growth-oriented and diversified company focused on the international cannabis industry and is developing a large scale Facility. The Retrofit of the Facility is split into three phases:

- Phase 1 – Retrofit of the 350,000 square feet, including post-production facilities, scheduled for completion in Q1 2019;
- Phase 2 – Additional 1,450,000 square feet, to be completed by Q4 2019; and,
- Phase 3 – Additional 400,000 square feet.

Agraflora also has ownership of several cannabis companies, including AAA Heidelberg and Propagation Services Canada, a large-scale greenhouse project in Australia, and is pursuing several other opportunities within the cannabis industry.

On March 18, 2019, the Company acquired all of the issued and outstanding shares of DOC that it did not otherwise own, for 54,687,503 Units of the Company. Each Unit consists of one common share of the Company and one Warrant that is exercisable into one common share of the Company at a price of \$0.65 until December 5, 2020. Through the acquisition of DOC, the Company controlled 89,704,080 common shares of Agraflora and the earn-in Agreement with Agraflora.

Corporate Highlights – Operations (Continued)

Delta Organic Cannabis (“DOC”) (Continued)

During the three-month period ended March 31, 2019, the Company sold 44,582,040 common shares for gross proceeds of \$22,291,020 and realized a loss of \$3,120,743. As at March 31, 2019, the Company controls 44,852,040 common shares of Agraflora representing 10.12% of the issued and outstanding shares of Agraflora on a non-diluted basis and a 10% of the earn-in interest in the Facility.

On May 23, 2019, the Company entered into a binding letter of intent, whereby Agraflora will purchase 100% of the Company's assets, including the Company's 20% interest in the Delta Greenhouse Complex, an array of domestic downstream/production formulation operations and the rights to a trans-European distribution network.

Agraflora will issue 1.15 common shares of Agraflora for each common share of the Company at the time of closing.

Corporate Highlights - Letter of Intent

Canutra Naturals Ltd.

On April 12, 2019, the Company entered into a letter of intent to acquire 100% of the issued and outstanding common shares of Canutra Naturals Ltd. (“Canutra”). Canutra is a Canadian Cannabidiol (“CBD”) cosmetic/topical manufacturing company, equipped with vertically integrated, farm to face model. Directly and through trade partners, Canutra cultivates, extracts, manufactures, and markets its premium skincare, cosmetics and cannabinoid product lines from its flagship facility in Kent County, New Brunswick. Canutra is dedicated to improving the health and wellness of the consumer population through the research, development and streamlined delivery of revolutionary cannabis/CBD products and technologies.

Canutra has developed a suite of trusted consumer brands, including Whole Hemp Health, a Canadian allnatural, hand-made skincare line; formulated with organic hemp seed oil. Canutra markets its Whole Hemp Health product line byway of brick-and-mortar retail outlets, Amazon Prime, as well as direct-to-consumer; through Canutra's integrated Shopify e-commerce platform; www.wholehemphealth.ca.

Potluck Potions and Edibles Inc.

On April 22, 2019, the Company entered into a binding letter of intent to acquire 80% of Potluck Potions and Edibles Inc. (“Potluck”). Potluck specializes in the management of beverage industry supply chains, including the bottling and manufacturing of a variety of beverages (the “Bottler” of the “Facility”).

Under the terms of the agreement, the Company will issue 10 million common shares upon execution of the definitive supply and distribution agreement and up to 6 million common shares upon the achievement of certain milestones.

The Bottler boasts extensive experience manufacturing for leading beverage brands such as Heineken, SABMiller as well as the Coca-Cola Company. The Facility is strategically situated in the Greater Toronto Area (the “GTA”) affording the Company unbridled access to the largest addressable Canadian marketplace. The GTA is buoyed by established infrastructure, offering the flexibility to accommodate shipments from multiple ports and hubs across North America.

Corporate Highlights - Letter of Intent (Continued)

Potluck Potions and Edibles Inc. (Continued)

The Facility can achieve throughput of up to 30-million bottles per year and is equipped with state-of-the-art bottling equipment; configured to conduct rapid production runs, with minimal downtime for production line changeovers. The Facility is fully operational and has been granted the following industry certifications:

- Good Manufacturing Practices ("GMP");
- Canadian Organic Standards;
- Certified Vegan;
- Fair Trade Certification (ISO 17065); and
- Kosher Facility Status.
-

Through the acquisition of Potluck, the Company plans to leverage the Facility to produce a suite of both cannabinoid-infused and functional beverages. The Facility is presently configured to produce formulations for water, coffee, tea, juice and carbonated sodas in a variety of formats, including glass bottles, polyethylene terephthalate ("PET") bottles and aluminum cans. The Facility has the capabilities to develop and produce premium beverages that exceed market standards, by leveraging innovative industry technologies including:

- Pharmaceutical-grade mixing tanks;
- Advanced UV sterilization; and
- Custom Extended Shelf Life ("ESL") bottling lines.

The functional beverage category is increasingly becoming the popular choice among consumers who are seeking low-calorie, nutrient dense options as a healthy alternative to traditional beverages. The global functional beverage market is expected to grow at a compound annual growth rate (CAGR) of 6.1 per cent to \$93.68-billion (U.S.) by 2019, according to a new study by Grand View Research Inc. Organic Flower's functional beverage formulations will address major and growing consumer health and wellness needs for the modern lifestyle.

Corporate Highlights - Strategic Agreements

Edibles and Infusions Corporation

On April 26, 2019, the Company entered into a definitive agreement ("Purchase Agreement") to acquire 80% interest in the Edibles and Infusions Corporation ("Edibles and Infusions"). Upon execution of the Purchase Agreement, the Company conceived a joint-venture ("JV") with one of North America's largest and most storied manufacturer and distributor of chocolate and confectionary products.

Edibles and Infusions will design and develop a 50,000 square foot manufacturing and product formulation facility (the "Facility"), located in Winnipeg, Manitoba. The Facility will be operated by a roster of experienced chocolatiers and confectioners, as well as equipped with industry leading manufacturing equipment capable of producing an assortment of both cannabinoid/terpene-infused products for medicinal, functional and adult-use, including:

- Gourmet snacks, including caramel popcorn, cheese biscuits, cocoa cookies, glazed pecans, and salty pretzels;
- Chocolates/toffees/caramels;
- Gummies/confectionary/gum;
- Baked goods;
- Flavoured tinctures; and
- Powdered drinks.

Corporate Highlights - Strategic Agreements (Continued)

Edibles and Infusions Corporation (Continued)

CBD-infused pet products Edibles and Infusions is working to finalize its applications for a Health Canada Standard Processing License, as well as a Cannabis Sales License. Organic Flower anticipates the Facility will be fully operational by the first quarter of 2020 and once optimized will be capable of generating in excess of \$750 million in annual sales revenue.

As consideration, the Company will issue or pay the following:

- \$10 million at closing, comprised of common shares of the Company (20,000,000 common shares issued subsequently);
- Up to \$32.5 million common shares of the Company at an attributed price equal to a 5 day VWAP at the time of issuance, upon the JV achieving certain milestones throughout 2022;
- Fund up to \$15 million to develop a facility; and
- \$9 million common shares to the manager of the JV based on certain milestones.

The Company also acquired an option ("Option") to purchase certain business assets of Edibles and Infusions for the purchase price of \$12.5 million.

As consideration, the Company will issue:

- \$1 million for the option to be exercisable within 6 months of the Option grant (2,485,726 common shares issued subsequently); and
- An additional 1 million of the Company to extend the exercise period by 6 months.

The Company issued 2,000,000 common shares to arm's length parties in connection with the acquisition of Edibles and Infusions.

CanaBeer

On May 7, 2019, the Company entered into a definitive agreement to acquire 80% of 11353675 Canada Corp, d/b/a CanaBeer ("CanaBeer"). CanaBeer holds claim to an exclusive formulation, manufacturing and distribution rights for all cannabinoid-infused beverages developed at a leading Toronto-based brewery (the "Brewhouse").

The Brewhouse is nearing completion of major facility retrofit initiatives, which are projected to increase its output capacity to over 200,000 HL per annum. Upon completion of the retrofit, aggregate capital expenditures deployed on the Brewhouse build-out will exceed \$20 million.

As consideration, the Company will issue 9,166,000 common shares of the company, based on the five-day VWAP of the Company's common shares for the five trading sessions prior to the announcement of the definitive agreement. A finder's fee is payable on this transaction.

ICC International Cannabis Corp.

On May 8, 2019, the Company entered into a distribution and cannabis processing/finishing agreement (the "Downstream Agreement") with ICC International Cannabis Corp. ("ICC"). ICC will permit the Company access to its European distribution network, comprised of 80,000 retail outlets and pharmacies and grant the Company commercial rights for cannabis processing/finishing at its EU-GMP certified facilities.

The Company will leverage ICC's expansive downstream footprint, to distribute its diverse product offering, including:

- Dried cannabis flower;
- Functional foods and beverages;
- CBD-infused pain relief creams and roll-ons;
- Hemp-oil based organic cosmetics and personal care products;
- Premium adult-use beverages; and
- Cannabinoid/terpene-infused edible products.

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)
Management's Discussion and Analysis
March 31, 2019 and 2018

Corporate Highlights - Strategic Agreements (Continued)

ICC International Corp. (Continued)

By way of an exclusive agreement, International Cannabis is equipped with a trans-European distribution network, spanning 16 countries, including: Germany, United Kingdom, Ireland, Denmark, Italy, France, Singapore, Spain, Poland, the Netherlands and Greece. ICC's European distribution network is augmented by various value-added services, including:

- Strategic procurement;
- Warehousing;
- Product registration; and
- Regulatory representations.

Toronto Wolfpack and Howl Brands

On May 13, 2019, ICC and the Company entered into a definitive agreement with Toronto Wolfpack RLFC ("Toronto Wolfpack") and HowlBrands to manufacture and distribute a suite of athlete-focused, cannabidiol performance products. Under the terms of the agreement, the Company issued 6,725,239 common shares.

Canada Cannabis Therapeutics Company and Colorado Science Company

In May 2019, the Company entered into two definitive agreements to acquire 80% of Canada Cannabis Therapeutics Company ("CCTC") and Colorado Science Company ("Colorado Science") by issuing 5 million common shares to the shareholders of CCTC and another 5 million shares to the shareholders of Colorado Science. Colorado Science holds claim to a number of cannabinoid product formulations equipped with patented micro-diffusion technology.

Discussion of Operations

The following is a breakdown of the expenses incurred by the Company for the three and nine- month period ended March 31, 2019 and 2018:

	For the three months ended		For the nine months ended	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
		(note 12 - restated)		(note 12 - restated)
Net investment gain (loss)				
Fair value gain (loss) change in investments	\$ 8,410,045	\$ (730,010)	\$ 7,701,177	\$ 714,787
Gain (loss) on sale of investments	(769,180)	22,564	(769,180)	82,996
	7,640,865	(707,446)	6,931,997	797,783
Expenses				
Accretion of convertible debentures	-	(13,242)	(159,191)	(40,314)
Consulting	(199,668)	-	(214,918)	-
Management and administrative	5,000	(16,841)	(33,929)	(41,841)
Filing and transfer fees	(22,522)	(6,026)	(88,236)	(28,074)
Foreign exchange loss	1,621	884	(1,187)	859
Office and other miscellaneous	(22,643)	(167)	(23,048)	(333)
Professional fees	(200,990)	(5,335)	(320,312)	(28,335)
Share-based compensation	-	-	(479,137)	-
Travel	-	-	-	(3,054)
Transaction costs	(2,351,562)	-	(2,351,562)	-
Interest on convertible debt	-	(49,238)	(28,996)	(149,902)
	(2,790,764)	(89,965)	(3,700,516)	(290,994)
Net income (loss) for the period	4,850,101	(797,411)	3,231,481	(506,789)
Loss on conversion of convertible loan	-	-	(886,643)	-
Net income (loss) and comprehensive income (loss) for the period	\$ 4,850,101	\$ (797,411)	\$ 2,344,838	\$ (506,789)

Discussion of Operations (continued)

Nine month period ended March 31, 2019 compared to the nine month period ended March 31, 2018:

- The Company's investment has evolved and changed over the past year. The change in fair value is primarily attributed to the addition of Agraflora common shares to the Company's investment portfolio via the acquisition of DOC. During the nine month period ended March 31, 2019, the Company recorded a gain on fair value of investments of \$7,701,177. In the comparative period, the Company saw gains in their energy sector investments, and recorded a fair value gain of \$714,787.
- The Company sold 44,582,040 Agraflora common shares for gross proceeds of \$22,291,020 and realized a loss of \$769,180. In the comparative period, the Company During the period ended March 31, 2018, the Company sold 140,000 shares of Pentanova Energy Corp for net proceeds of \$56,489 and realized a loss of \$16,676 on the sale, 60,000 shares of Leagold Mining Corp. for net proceeds of \$182,108 and realized a gain of \$77,108, 114,000 shares of Cabral Gold Inc. for net proceeds of \$34,407 and a realized gain of \$31,557 and 30,000 shares of Oronova for net proceeds of \$2,815 and a realized loss of \$8,993.
- Accretion of convertible debentures increased as the Company converted the convertible debt earlier than the life of the debt. This resulted in an increase in convertible debt relative to comparative period.
- Consulting and professional fees increased as the Company executed two private placements during the period and converted the Company's convertible debt. Furthermore, the Company completed due diligence on prospective investments including DOC, investigated several strategic alliances, restructured its share capital and incurred accounting fees. These factors resulted in an overall increase in professional fees during the period as the comparative period was fairly inactive.
- Filing and transfer agent fees increased as the Company filed more press releases than the comparative period. In general, there was an overall increase in activity in the Company.
- During the current period, the Company granted 3,564,112 stock options to various consultants of the Company with an exercise price of \$0.16 with a 10-year term and 1,000,000 stock options to a consultant of the Company with an exercise price of \$0.45 with a 5 year term. The estimated fair value of the stock options was \$479,137, measured using the Black-Scholes Option Pricing Model. The Company did not grant stock options in the comparative period.
- Interest decreased as the Company converted the Company's convertible debt during the quarter.
- On August 21, 2018, the Company converted \$1,331,250 of convertible debt into units of the Company. The fair value of the common shares on the date of conversion was \$3,727,500. The equity and liability portion of the convertible debt totaled \$2,840,857 resulting in a loss on conversion of convertible debt of \$886,643.
- In connection with the acquisition of DOC, the Company issued 5,468,750 common shares with a fair value of \$2,351,563 and expensed them as transaction costs.

During the three-month period ended March 31, 2019, the Company incurred income (loss) and comprehensive income (losses) of \$4,850,101 compared to (\$797,411). The Company generated a comprehensive income in the comparative period due to an unrealized fair value gain on investment. A significant amount of the overall expenditures was incurred during the three-month period ended December 31, 2018 and the explanations of the nature of costs incurred are similar to the above descriptions with the exception of the following:

- During the third quarter of 2018, the fair value of Company's energy investments decreased significantly and posted a fair value loss of \$730,010 during the third quarter of 2018. This contrasts the third quarter of 2019, where the significant increase in Agraflora resulted in an overall fair value gain of \$8,410,045.

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)
Management's Discussion and Analysis
March 31, 2019 and 2018

Summary of Quarterly Results

The following table presents selected unaudited consolidated financial information for the previous eight quarters:

(CAD\$)	2019			2018				2017
Period Ending	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Net investment (loss) income	7,640,865	(297,192)	(411,676)	(1,038,830)	(731,014)	1,306,066	137,451	898,354
Net income (loss)	4,850,101	(438,523)	(2,066,740)	(1,213,082)	(798,761)	1,198,285	105,379	697,958
Basic income (loss) per Share	0.05	(0.00)	(0.10)	(0.39)	(0.26)	0.39	0.03	0.23
Diluted income (loss) per Share	0.05	(0.00)	(0.10)	(0.36)	(0.24)	0.36	0.03	0.21

The quarterly financial information for the 2019, 2018 and 2017 fiscal periods, are presented in accordance with IFRS.

During Q3 2019, the Company acquired the remainder of DOC, resulting in the control of DOC's Agraflores shares. During Q3 2019, Agraflores shares out-performed and resulted in a significant fair value gain in change of investment. This resulted in a significant increase in net investment income.

Since fiscal 2009, the Company has been negatively impacted by poor stock market performance, volatile commodity prices, and substantially weakened global economic performance. Quarter-to-quarter performance is affected by the timing of specific write-downs. There was an increase in losses between 2018 Q4 to 2019 Q1 as the Company recorded a one-time loss of \$886,643 on the conversion of convertible debt and an unrealized loss of investment income. Q4 2017 to Q2 2018 saw net investment income and net income increase due to a short-term unrealized gain on investment.

Liquidity

As at March 31, 2019, the Company had working capital of \$52,080,428 compared to working capital of \$1,253,307 as at June 30, 2018. Cash as at March 31, 2019 was \$2,604,502 compared to \$1,933 as at June 30, 2018. The Company has limited resources, limited source of operating cash flow, and no assurance that sufficient funding will be available. Management does have the option to raise funds through the sale of Company investments, debt and or equity financing. The success of these plans will depend upon future events, and the Company's abilities to achieve profitability and positive cash flows is uncertain. These material uncertainties cast significant doubt upon the Company's ability to continue as a going concern.

Capital Resources

During the period ended March 31, 2019, the fair value change in investments was a gain of \$8,410,045 compared to a gain of \$714,787 during the period ended March 31, 2018.

The Company has no assurance that additional funding will be available to it for investment opportunities or future projects. There can be no assurance that it will be able to obtain adequate financing in the future or that the terms of such financing will be favorable. Failure to obtain such additional financing could result in a delay or indefinite postponement of further investment opportunities or future projects.

Operating Activities

Cash used in operating activities during the period ended March 31, 2019 was \$681,630 compared to cash used in operating activities of \$100,778 during the period ended March 31, 2018.

Organic Flower Investments Group Inc.
(Formerly Q Investments Ltd.)
Management's Discussion and Analysis
March 31, 2019 and 2018

Financing Activities

Cash provided by financing activities was \$8,429,635 compared to \$nil in the comparative period. The Company completed a private placement, raising \$8,491,124. The Company also exercised stock options and warrants for gross proceeds of \$63,000 and \$311,540, respectively. The Company used a large portion of the finances to make its strategic investment in DOC.

The Company also paid \$436,030 in accrued interest on the convertible debt.

Investing Activities

During the period ended March 31, 2019, the Company's net cash used in (provided by) investing activities was \$5,208,980 compared to (\$75,720). The Company made its first strategic investment into the cannabis market, investing \$7,500,000 at \$1.00 per share, for 7,500,000 common shares of DOC. The Company completed the acquisition of DOC and sold Agraflora shares for proceeds of \$22,291,020. The Company used these proceeds to purchase more Agraflora for \$27,500,000. In the comparative period, the Company sold 140,000 shares of Pentanova Energy Corp for net proceeds of \$56,489 and realized a loss of \$16,676 on the sale, 60,000 shares of Leagold Mining Corp. for net proceeds of \$182,108 and realized a gain of \$77,108, 114,000 shares of Cabral Gold Inc. for net proceeds of \$34,407 and a realized gain of \$31,557 and 30,000 shares of Oronova for net proceeds of \$2,815 and a realized loss of \$8,993.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet financing arrangements.

Transactions with Related Parties

The Directors and Executive Officers of the Company are as follows:

John Martin	Director
Theo Van Der Linde	Director
Joel Dumaresq	Director, interim Chief Financial Officer
Brendan Purdy	Director

The following is a summary of related party transactions that occurred during the period ended March 31, 2019 that have not otherwise been disclosed:

- a) Included in accounts payable and accrued liabilities is \$38,200 (June 30, 2018 - \$13,261) payable to officers and directors of the Company. Amounts due to related parties have no stated terms of interest and/or repayment.

Key management personnel include the directors and officers of the Company. Key management compensation consists of the following:

	March 31, 2019 \$	March 31, 2018 \$
Management and administrative fees paid or accrued to a company controlled by the CFO	12,208	19,341
Management and administrative fees paid or accrued to a company controlled by the President	14,130	-
Consulting fees paid or accrued to a company controlled by Joel Dumaresq	25,000	-
Consulting fees paid or accrued to a company controlled by Theo Van Der Linde	28,000	-
Management and administrative fees paid to a company controlled by the former President	7,500	22,500

Transactions with Related Parties (continued)

There were no post-employment benefits, termination benefits or other long-term benefits paid to key management personnel for the period ended March 31, 2019 and 2018.

The significant accounting policies used by the Company are disclosed in Note 3 of our audited annual Financial Statements for the year ended June 30, 2018 and in our condensed interim consolidated financial statements for the period ended March 31, 2019. The company adopted the following accounting policies as of March 31, 2019:

Share Capital

During the period ended March 31, 2019, the Company's share structure changed to unlimited common shares with no par value.

IFRS 9 – Financial Instruments

IFRS 9 was issued by the International Accounting Standards Board ("IASB") in November 2009 and October 2010 and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Two measurement categories continue to exist to account for financial liabilities in IFRS 9, FVTPL and amortized cost. Financial liabilities held-for-trading are measured at FVTPL, and all other financial liabilities are measured at amortized cost unless the fair value option is applied. The treatment of embedded derivatives under the new standard is consistent with IAS 39 and is applied to financial liabilities and non-derivative hosts not within the scope of the standard. IFRS 9 introduces an 'expected credit loss' model for the impairment of financial assets. The measurement of the Company's financial assets and liabilities will not significantly change on transition to IFRS 9. Additionally, the Company is exposed to minimal expected credit losses due to the fact that it has an insignificant amount of accounts receivable. The Company has adopted the amendments to IFRS 9 in its financial statements for the annual period beginning on August 1, 2018 with no resulting adjustments.

IFRS 15 – Revenue with Contracts

IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It has replaced IAS 18 Revenue, IAS 11 Construction Contracts and related interpretations. The new standard establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer.

The Company has adopted the amendments to IFRS 15 in its financial statements for the annual period beginning on August 1, 2018 with no resulting adjustments.

New Accounting Pronouncements

The following new pronouncements will be effective in future periods:

IFRS 16 Leases

This new standard sets out the principles for the recognition, measurement, presentation and disclosure of leases for both the lessee and the lessor. The new standard introduces a single lessee accounting model that requires the recognition of all assets and liabilities arising from a lease.

The main features of the new standard are as follows:

- An entity identifies as a lease a contract that conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

IFRS 16 Leases (continued)

- A lessee recognizes an asset representing the right to use the leased asset, and a liability for its obligation to make lease payments. Exceptions are permitted for short-term leases and leases of low-value assets.
- A lease asset is initially measured at cost, and is then depreciated similarly to property, plant and equipment. A lease liability is initially measured at the present value of the unpaid lease payments.
- A lessee presents interest expense on a lease liability separately from depreciation of a lease asset in the statement of profit or loss and other comprehensive income.
- A lessor continues to classify its leases as operating leases or finance leases, and to account for them accordingly.
- A lessor provides enhanced disclosures about its risk exposure, particularly exposure to residual-value risk.

The new standard supersedes the requirements in IAS 17 Leases, IFRIC 4 Determining Whether an Arrangement Contains a Lease, SIC-15 Operating Leases – Incentives and SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease.

Applicable to the Company's annual period beginning July 1, 2019.

Financial Instruments and Other Instruments

Fair Value of Financial Instruments

Classification and fair value of financial instruments:

Classification

The Company classifies its financial instruments into categories as follows: cash and investments, as financial assets at FVTPL; convertible debenture, accounts payable and accrued liabilities, and loans payable, as other financial liabilities.

Fair value

Cash and investments, consisting of marketable securities, are carried at fair market value based on quoted market prices in an active market. The carrying values of accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these financial instruments.

Convertible debenture was initially valued under Level 3 of the fair value hierarchy using a discount rate of 17%, which was based on similar debt for comparable companies. Subsequent measurement is carried at amortized cost. As at March 31, 2019, the principal and accrued interest is \$Nil (2018 - \$1,579,095).

Financial Instruments and Other Instruments (Continued)

The Company's measurement of the fair value of financial instruments as at March 31, 2019 and June 30, 2018 in accordance with the fair value hierarchy is as follows:

	Total	Level 1	Level 2	Level 3
March 31, 2019				
Cash	\$ 2,604,502	\$ 2,604,502	\$ -	\$ --
Investments	\$ 49,584,888	\$ 587,923	\$ -	\$ 48,996,965
June 30, 2018				
Cash	\$ 1,933	\$ 1,933	\$ -	\$ -
Investments	\$ 1,296,791	\$ 1,296,791	\$ -	\$ -

FINANCIAL RISK MANAGEMENT

(a) Overview

The Company has exposure to the following risks from its use of financial instruments:

- Market risk;
- Credit risk; and
- Liquidity risk.

(b) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: interest rate risk, foreign currency risk and other price risk.

(i) Interest rate risk

The Company's cash is held in bank accounts, which have nominal interest rates attached to them; therefore, fluctuations in market interest rates would not have a material impact on their fair values as at March 31, 2019 and 2018.

The Company's convertible debentures have fixed interest rates of 15% per annum. During the period ended March 31, 2019, the Company converted its convertible debt. As at March 31, 2019, the principal and accrued interest is \$Nil (2018 - \$1,579,095). As such, the Company's cash flow would not be impacted by changes in market rates of interest.

(ii) Foreign currency risk

The Company is exposed to financial risk related to the fluctuation of foreign exchange rates. The Company's functional currency is the Canadian dollar and the condensed interim consolidated financial statements are presented in Canadian dollars. The Company is not exposed to significant foreign currency risk.

(ii) Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk and foreign currency risk. The Company holds certain marketable securities that will fluctuate in value as a result of fluctuations in current market prices of those securities. Furthermore, as the Company's marketable securities are resource exploration and cannabis companies, market values will fluctuate subject to the price of cannabis and its derivatives, commodity prices, economic cycles and political events. Based upon the Company's investment portfolio at March 31, 2019, a 96% (2018 - 96%) increase or decrease in the market price of the securities held would result in an increase/decrease to net income (loss) and comprehensive income (loss) of approximately \$ 4,900,000 (2018 - \$1,801,000).

(c) Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its payment obligations. The Company's exposure to credit risk is limited to its cash balances. The risk exposure is limited to the carrying amounts at the statement of financial position dates.

FINANCIAL RISK MANAGEMENT (CONTINUED)

The Company's cash balances are held in accounts at a major Canadian financial institution. The credit risk associated with cash is mitigated, as cash is held at major institutions with high credit ratings.

Concentration of credit risk and maximum exposure thereto exists as follows:

	March 31, 2019	June 30, 2018
Cash	\$ 2,604,502	\$ 1,933

(d) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company assesses its liquidity risk by forecasting cash flows required by operations and anticipated financing activities.

The Company has a cash balance at March 31, 2019 of \$2,604,502 (2018 - \$1,933) and investments with a fair value of \$46,584,888 (2018 - \$1,296,791). At March 31, 2019, the Company has accounts payable and accrued liabilities of \$137,325 (2018 - \$45,417). As at March 31, 2019, the Company has working capital of \$52,080,427 (2018 - \$ 1,253,307). The Company relies upon financing to maintain sufficient working capital. There is no assurance that such financing will be available on terms and conditions acceptable to the Company.

The Company's accounts payable and accrued liabilities, are due in the short-term (0 to 3 months).

Hedges

The Company does not apply hedge accounting.

Legal Matters

The Company is not currently, or at any time during our most recently completed financial year, been a party to any material legal proceedings or regulatory actions.

Business Risks and Uncertainties

Certain risks and uncertainties that could cause the Company's actual results to materially differ from our current expectations include, but are not limited to:

Going Concern

The Company's comprehensive income of \$2,344,838 for the period ended March 31, 2019 (2018 – loss of \$506,789), and as at March 31, 2019, has a working capital of \$52,080,427 (June 30, 2018 - \$1,253,307), an accumulated deficit of \$24,893,653 (June 30, 2018 - \$29,238,491), limited resources, limited source of operating cash flow and no assurances that future funding will be available if required. Management has the option to raise funds through the sale of investments. The success of these plans will depend upon future events, and the Company's ability to achieve profitability and positive cash flows is uncertain. These material uncertainties cast significant doubt upon the Company's ability to continue as a going concern.

These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary, should the Company be unable to continue as a going concern.

Business Risks and Uncertainties (continued)

Sector Specific Investment Risks

The Company seeks a high return on investment opportunities on its cannabis, mining and natural resource sectors ("Sectors"). Thus, the Company is exposed to investment risks relating to these Sectors which is generally more volatile than the overall market. Investing in these Sectors can be speculative in nature and the value of the Company's investments may be subject to significant fluctuations. Such businesses entail a degree of risk, regardless of the skill and experience of the corporation's management. The assets, earnings and share values of corporations involved in the cannabis, mining and natural resource are subject to risks associated with the world prices of various cannabis related products, natural resource, forces of nature, economic cycles, commodity prices, exchange rates, royalty and taxation changes and political events. Government restrictions, such as price regulations, production quotas, royalties and environmental protection, can also be factors.

Regulatory Risks

The Company's investment in the cannabis sector operate in a new industry which is highly regulated, highly competitive and evolving rapidly. As such, new risks may emerge, and management may not be able to predict all such risks or be able to predict how such risks may result in actual results differing from the results contained in any forward-looking statements. The Company's investments incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional costs for corrective measures, penalties or in restrictions of operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company's investment and, therefore, on the Company's prospective returns.

The industry is subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The marketability of any product may be affected by numerous factors that are beyond the control of the Company which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce the Company's earnings and could make future capital investments or the Company's operations uneconomic. The industry is also subject to numerous legal challenges, which may significantly affect the financial condition of market participants and which cannot be reliably predicted.

Change in Law, Regulations and Guidelines

The Company's investments are subject to a variety of laws, regulations and guidelines relating to marketing, acquisition, manufacture, management, transportation, storage, sale and disposal of cannabis pharmaceuticals and cannabis pharmaceutical related products but also laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Changes to such laws, regulations and guidelines may cause adverse effects to the Company's investments in the cannabis pharmaceutical sector.

Jurisdictions Outside of Canada

The Company intends to invest into early-stage global cannabis related Company's with operations and business that may be outside of Canada's jurisdiction. There can be no assurance that any market for the Company's Investment Partners products will develop in any such foreign jurisdiction. The Company may face new or unexpected risks or significantly increase its exposure to one or more existing risk factors, including economic instability, changes in laws and regulations and the effects of competition. These factors may limit the Company's capability to successfully invest in foreign cannabis pharmaceutical entities and may have a material adverse effect on the Company's business, financial condition and results of operations.

Business Risks and Uncertainties (continued)

Political and Economic Instability

The Company may be affected by possible political or economic instability. The risks include, but are not limited to, terrorism, military repression, extreme fluctuations in currency exchange rates and high rates of inflation. Changes in medicine and agriculture development or investment policies or shifts in political attitude in certain countries may adversely affect the Company's business. Operations may be affected in varying degrees by government regulations with respect to restrictions on production, distribution, price controls, export controls, income taxes, expropriation of property, maintenance of assets, environmental legislation, land use, land claims of local people and water use. The effect of these factors cannot be accurately predicted.

Limited Operating History

The Company has limited operating history as an investment company, and has had limited success investing in mining and cannabis sectors. The Company and its business prospects must be viewed against the background of the risks, expenses and problems frequently encountered by companies in the early stages of their development, particularly companies in new and rapidly evolving markets such as the cannabis sectors. There is no certainty that the Company will be able to operate profitably.

Additional Requirements for Capital

Substantial additional financing may be required if the Company is to be successful in developing a diversified and material portfolio of investments. No assurances can be given that the Company will be able to raise the additional capital that it may require for its anticipated future development. Any additional equity financing may be dilutive to investors and debt financing, if available, may involve restrictions on financing and operating activities. There is no assurance that additional financing will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations or anticipated investments.

Key Personnel

The Company is dependent upon the continued availability and commitment of its management, whose contributions to immediate and future operations are of significant importance. The loss of any such management could negatively affect the Company's business operations. From time to time, the Company will also need to identify and retain additional skilled management to efficiently operate its business. Recruiting and retaining qualified personnel is critical to the Company's success and there can be no assurance of its ability to attract and retain such personnel. If it is not successful in attracting and training qualified personnel, the Company's ability to execute its business model and growth strategy could be affected, which could have a material and adverse impact on its profitability, results of operations and financial condition.

Lack of Control or significant influence over Companies in which the Company Invests

In certain cases, the Company invests or may invest in securities of companies that the Company does not control or influence. These investments will be subject to the risk that the company in which the investment is made may make business, financial or management decisions with which the Company does not agree or that the majority stakeholders or management of the company may take risks or otherwise act in a manner that does not serve the Company's interests. If any of the foregoing were to occur, the values of investments by the Company could decrease and the Company's financial condition and cash flow could suffer as a result.

Business Risks and Uncertainties (continued)

Due Diligence

The due diligence process undertaken by the Company in connection with investments that it makes or wishes to make may not reveal all relevant facts in connection with an investment. Before making investments, the Company will conduct due diligence investigations that it deems reasonable and appropriate based on the facts and circumstances applicable to each investment. When conducting due diligence investigations, the Company may be required to evaluate important and complex business, financial, tax, accounting, environmental and legal issues. Outside consultants, legal advisors, accountants and investment banks may be involved in the due diligence process in varying degrees depending on the type of investment. Nevertheless, when conducting due diligence investigations and making an assessment regarding an investment, the Company will rely on resources available, including information provided by the target of the investment and, in some circumstances, third party investigations. The due diligence investigations that are carried out with respect to any investment opportunity may not reveal or highlight all relevant facts that may be necessary or helpful in evaluating such investment opportunity. Moreover, such investigation will not necessarily result in the investment being successful.

Fluctuations in the Value of the Company and the Common Shares

The net asset value of the Company and market value of its common shares will fluctuate with changes in the market value of the Company's investments. Such changes in value may occur as the result of various factors, including general economic and market conditions, the performance of corporations whose securities are part of the Company's investment portfolio and changes in interest rates which may affect the value of interest-bearing securities owned by the Company. There can be no assurance that shareholders will realize any gains from their investment in the Company and may lose their entire investment.

Need to Manage Growth

The Company could experience rapid growth in revenues, personnel, complexity of administration and in other areas. There can be no assurance that the Company will be able to manage the impact that growth could place on the Company's administrative infrastructure, systems and controls. If the Company is unable to manage future growth effectively, the Company's business, operations and operating results and financial condition may be materially adversely affected.

Outstanding Share Data

The Company's shares are traded on the CSE under the symbol "SOW," under the symbol "QILFF" on the OTC Pink and on the Frankfurt Stock Exchange under the symbol "2K6."

As of as of the date of this MD&A, the Company has the following securities outstanding:

Class of Shares	Number Issued
Common	207,851,106

There are 20,094,112 options and 152,766,425 Warrants outstanding and no common shares held in escrow or subject to pooling.

ADDITIONAL DISCLOSURE FOR VENTURE ISSUERS WITHOUT SIGNIFICANT REVENUE

Additional disclosure concerning the Company's general and administrative expenses is provided in the Company's consolidated statement of income (loss) and comprehensive income (loss) and note disclosures contained in its consolidated financial statements for the period ended March 31, 2019. These consolidated financial statements are available on SEDAR - Site accessed through www.sedar.com.

Additional Information

Additional information relating to our Company, including periodic quarterly and audited financial reports, is available on SEDAR at www.sedar.com.